• Badri M, Cleary S et al. 2006. When to initiate HAART in sub-Saharan Africa? A South African cost-effectiveness study. Antiviral Therapy 11:6372.
  • Birch S, Donaldson C. 1987. Applications of cost–benefit analysis to health care – departures from welfare economic theory. Journal of Health Economics 6:211225.
  • Birch S, Gafni A. 1992. Cost-effectiveness/utility analyses. Do current decision rules lead us to where we want to be? Journal of Health Economics 11:279296.
  • Birch S, Gafni A. 2006. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. Journal of Health Service and Research Policy 11(1):4651.
  • Cleary S, McIntyre D et al. 2006. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Effectiveness and Resource Allocation 4:20.
  • Cleary S, Mooney G et al. 2008. Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting. Under review in Health Economics.
  • Donaldson C. 1998. The (Near) equivalence of cost-effectiveness and cost–benefit analyses. Pharmacoeconomics 13(4):386396.
  • Donaldson C, Currie G et al. 2002. Cost-effectiveness analysis: contra-indications. British Medical Journal 325:891894.
  • Drummond M, Jefferson T. 1996. Guidelines for authors and peer reveiwers of economic submissions to the BMJ. British Medical Journal 313:275283.
  • HIV and AIDS and STI National Strategic Plan 2007–2011. 2007. Pretoria, South African National AIDS Council (SANAC): 1136.
  • Loubiere S, Marhoum El Filal K et al. 2008. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience. Antiviral Therapy 13(2):241251.
  • UNAIDS 2007. AIDS epidemic update: December 2007, Joint United Nations Programme on HIV/AIDS and World Health Organisation.
  • WHO and UNAIDS 2004. Consultation on ethics and equitable access to treatment and care for HIV/AIDS. Geneva, World Health Organisation/Joint United Nations Programme on HIV/AIDS.
  • Yazdanpanah Y, Losina E et al. 2005. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 19(12):12991308.